This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO)

Tipranks - Tipranks - Tue Jun 16, 6:04AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO).

Claim 55% Off TipRanks

Incyte (INCY)

In a report released yesterday, Derek Archila from Wells Fargo maintained a Hold rating on Incyte, with a price target of $101.00. The company’s shares closed last Friday at $108.53.

According to TipRanks.com, Archila is a 5-star analyst with an average return of 18.9% and a 53.2% success rate. Archila covers the Healthcare sector, focusing on stocks such as First Tracks Biotherapeutics Inc, Kyverna Therapeutics, Inc., and Monte Rosa Therapeutics. ;'>

Currently, the analyst consensus on Incyte is a Moderate Buy with an average price target of $111.47, representing a 3.4% upside. In a report issued on June 8, William Blair also maintained a Hold rating on the stock.

See Insiders’ Hot Stocks on TipRanks >>

Intellia Therapeutics (NTLA)

In a report released yesterday, Joseph Thome from TD Cowen maintained a Buy rating on Intellia Therapeutics. The company’s shares closed last Friday at $12.11.

According to TipRanks.com, Thome is a 5-star analyst with an average return of 20.9% and a 55.2% success rate. Thome covers the Healthcare sector, focusing on stocks such as MapLight Therapeutics, Inc., Amylyx Pharmaceuticals Inc, and Rapport Therapeutics, Inc. ;'>

Currently, the analyst consensus on Intellia Therapeutics is a Moderate Buy with an average price target of $21.06, which is a 71.4% upside from current levels. In a report released today, William Blair also reiterated a Buy rating on the stock.

Halozyme (HALO)

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Halozyme, with a price target of $75.00. The company’s shares closed last Friday at $69.50.

According to TipRanks.com, Bansal is a 5-star analyst with an average return of 9.7% and a 57.6% success rate. Bansal covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Vertex Pharmaceuticals, and Bristol-Myers Squibb. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Halozyme with a $85.80 average price target.

Read More on INCY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).